Summary
A series of 258 breast cancer patients with known estrogen receptor (ER) status of the primary tumour who subsequently developed metastases were reviewed for site of first metastasis. In 188 cases progesterone receptor (PgR) data were also available.
Univariate analysis showed metastatic patterns to differ statistically significantly related to ER status and (less pronounced) PgR status of the primary tumour. Patients with ER-positive tumours had bone metastases three times more often than patients with ER-negative tumours. With respect to PgR-positive and PgR-negative tumours this frequency differed by a factor of two. With regard to visceral metastases ER and PgR status were equally potent prognosticators, patients with receptor negative tumours having a 50% higher frequency of visceral metastasis than patients with receptor positive tumours. Assessment of metastatic patterns in relation to combined receptor status did not substantially enhance the discriminatory value of ER and PgR when assessed separately.
Multivariate analysis showed that the observed differences in metastatic patterns were all attributable to differences in the ER status of the primary tumour, and were not influenced by age, menopausal status, axillary lymph node involvement, duration of disease-free interval (DFI), mode of postoperative treatment, or the PgR status of the primary tumour.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tinnemans JGM, Beex LVAM, Wobbes Th, v/d Sluis RF, Raemakers JMM, Benraad ThJ: Steroid-hormone receptors in nonpalpable and more advanced stages of breast cancer: a contribution to the biology and natural history of carcinoma of the female breast. Cancer 66: 1165–1167, 1990
Alonko A, Heinonen E, Scheinin T, Tolppanen E, Vihko R: Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56: 1696–1700, 1985
Stuller I, Zielinski CC, Aiginger P, Rausch P, Potzi P, Kubista E, Salzer H, Sevelda P, Langer M, Staffen A, Spona J: Der Einfluss von Hormonrezeptoren auf die Metastasen Lokalisation beim Mammakarzinom. Onkologie 10: 302–303, 1987
EORTC Breast Cancer Co-operative Group: Revision of standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513–1515, 1980
Lowry OH, Rosebourgh NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275, 1951
SAS User's Guide: Statistics, version 5 edition, SAS Institute Inc, Box 8000, Cary, NC 27511-8000
Singhakowinta A, Potter HG, Buroker TR, Samal B, Brooks SC, Vaitkevicius VK: Estrogen receptor and natural cause of breast cancer. Ann Surg 183: 84–88, 1976
Campbell FC, Blamey RW, Elston CW, Nicholson RI, Griffiths K, Haybittle JL: Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer 44: 456–459, 1981
Stewart JF, King RJB, Sexton SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease, and survival in recurrent breast cancer. Eur J Cancer 17: 449–453, 1981
Quazi R, Chuang JC, Drobyski W: Estrogen receptors and the pattern of relapse in breast cancer. Arch Intern Med 144: 2365–2367, 1984
Clark GM, Sledge GW, Osborne CK, McGuire WL: Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55–61, 1987
Kamby C, Bruun Rasmussen B, Kirstensen B: Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 60: 253–257, 1989
Hahnel R, Woodings T, Brian A: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671–675, 1979
Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2–10, 1983
Valagussa P, Tesoro Tess JD, Rossi A, Tancini G, Banfi A, Bonadonna G: Adjuvant CMF effect on the site of first recurrence and appropriate follow-up intervals in operable breast cancer with positive axillary nodes. Breast Cancer Res Treat 1: 349–356, 1981
Author information
Authors and Affiliations
Consortia
Additional information
Including the Departments of Surgery (Th. Wobbes, R.F. v.d. Sluis), Radiotherapy (W.A.J. v. Daal), Pathology (R. Holland), Radiology (J.H.C.L. Hendriks), and Medical Oncology (D. Wagener)
Rights and permissions
About this article
Cite this article
Koenders, P.G., Beex, L.V.A.M., Langens, R. et al. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. Breast Cancer Res Tr 18, 27–32 (1991). https://doi.org/10.1007/BF01975440
Issue Date:
DOI: https://doi.org/10.1007/BF01975440